BioPorto
IVD company developing NGAL biomarkers for early acute kidney injury (AKI) risk assessment.
BIOPOR | CO
Overview
Corporate Details
- ISIN(s):
- DK0011048619
- LEI:
- 5299004SWFL5JAN4W830
- Country:
- Denmark
- Address:
- Tuborg Havnevej 15, st., 2900 Hellerup
- Website:
- https://bioporto.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
BioPorto is an in-vitro diagnostics (IVD) company focused on developing and commercializing actionable biomarkers to improve patient management and outcomes. The company's core technology centers on the NGAL biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI), a condition where traditional diagnostic methods are often delayed and non-specific. Its product portfolio includes The NGAL Test™, which is CE-marked and available internationally, and ProNephro AKI (NGAL), the first FDA-cleared biomarker test for pediatric AKI risk assessment. Additionally, BioPorto provides a range of NGAL ELISA kits for preclinical and clinical research, as well as antibodies for the development of various diagnostic immunoassays.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for BioPorto and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-15 07:56 |
Earnings Release
|
English | 738.6 KB | |
| 2025-08-15 07:56 |
Earnings Release
|
English | 17.0 KB | |
| 2025-08-15 07:56 |
Earnings Release
|
English | 738.6 KB | |
| 2025-08-15 07:56 |
Earnings Release
|
Danish | 16.9 KB | |
| 2025-06-27 09:19 |
Regulatory News Service
|
English | 7.4 KB | |
| 2025-06-27 09:19 |
Earnings Release
|
Danish | 7.4 KB | |
| 2025-06-10 16:19 |
Board/Management Information
|
Danish | 8.5 KB | |
| 2025-06-10 16:19 |
Board/Management Information
|
English | 7.9 KB | |
| 2025-06-10 16:19 |
Board/Management Information
|
English | 90.8 KB | |
| 2025-06-10 16:19 |
Board/Management Information
|
Danish | 119.0 KB | |
| 2025-04-25 13:55 |
Director's Dealing
|
English | 28.4 KB | |
| 2025-04-25 13:55 |
Director's Dealing
|
Danish | 155.6 KB | |
| 2025-04-25 13:55 |
Director's Dealing
|
English | 133.6 KB | |
| 2025-04-25 13:55 |
Director's Dealing
|
Danish | 28.7 KB | |
| 2025-04-25 13:45 |
Share Issue/Capital Change
|
English | 84.5 KB |
Automate Your Workflow. Get a real-time feed of all BioPorto filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for BioPorto via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
